ANGO: Flat Base detected on 6 May 2026

ANGO is forming a flat base pattern, a consolidation structure where price trades in a tight range, building foundation for potential breakout. The stock is trading at $10.96 with key support at $9.39 and resistance at $11.34. The structure score of 14.0/15 and breakout score of 10.0/13 indicate a moderately clean consolidation, though volume appears muted at 0.64x average (below ideal confirmation levels). The conservative measured move target sits at $11.43, roughly 4% above resistance. With an overall pattern quality score of 33.0/40, the setup shows technical merit but lacks exceptional volume confirmation needed for high-conviction breakouts.

AngioDynamics reported Q3 2026 earnings on April 2nd, beating estimates with ($0.07) EPS versus ($0.11) consensus, and delivering $78.42M revenue ahead of $76.77M expectations. The company raised full-year FY 2026 guidance for net sales and Adjusted EBITDA, and fiscal Q2 2026 showed net sales of $79.4M (+8.8% pro forma) with Med Tech sales up 13.0%. However, CEO Jim Clemmer announced his intention to retire upon appointment of a successor during fiscal 2027, introducing leadership transition uncertainty. In February 2026, ANGO announced expanded European indications for its NanoKnife System, adding soft tissue ablation for liver, pancreas, kidney, and prostate tumors. The company maintains a debt-free balance sheet, providing financial flexibility for growth investments.

A successful breakout above $11.34 resistance would target $11.43 (conservative target), with potential for acceleration toward $12.00+ if volume increases materially above the 377K share daily average. The 61.28% win probability indicates slightly better-than-even odds the pattern resolves upward. Invalidation occurs at $9.39 support—a close below this level negates the flat base setup and suggests weakness. Volume confirmation remains critical; breakouts on elevated volume (>1.0x ratio) historically show stronger follow-through than the current muted 0.64x ratio.

The announced CEO transition, with Jim Clemmer retiring during fiscal 2027, introduces leadership uncertainty that could dampen investor confidence during critical execution periods. Wall Street Zen downgraded shares to 'hold' on December 21st, signaling waning momentum among some analysts. Company guidance assumes tariff impacts as of January 6, 2026, but the situation remains fluid and could change materially. The stock trades 21.66% below its 52-week high of $13.99, suggesting prior weakness and resistance at elevated levels. With RSI at 52.52 (neutral, not overbought), the pattern lacks the momentum divergence that typically precedes strong breakouts. Volume remains the primary red flag—at 0.64x average, the consolidation lacks the conviction needed for reliable breakout execution in a healthcare sector currently in bearish regime (-0.0 score).